[Research Report] The infertility testing market is projected to grow from US$ 424.20 million in 2022 to US$ 820.08 million by 2030; the market is estimated to record a CAGR of 8.6% during 2022–2030.

Market Insights and Analyst View:

Factors such as the increasing cases of infertility in men and women and growing advancements in infertility testing propel the market growth. However, lack of awareness and limitations associated with infertility testing kits impede the market growth.

In the area of reproductive ability, infertility refers to a deficiency that neither affects the individual's physical performance nor is life-threatening. However, it could affect the development of individual (both men and women), weakening their personality and causing frustration. Approximately 50 to 80 million couples experience infertility problems at least once in their reproductive lives. The situation of infertility is different in developing countries than in developed countries. According to the World Health Organization (WHO), one in six couples suffers from infertility problems. Increasing awareness about testing and changing lifestyles with increasing trends of unhealthy diets leading to infertility and gynecological disorders in men and women are contributing to the growing infertility testing market size. Furthermore, technological advancements in ovulation monitors propel the market growth. Rising consumption of smoking and tobacco will lead to an increase in infertility cases, bolstering the demand for infertility testing. In addition, increasing awareness about fertility, the growing female population affected by PCOS, rising demand for self-testing and remote monitoring testing among men and women, and innovation of new products are expected to create opportunities for the infertility testing market during the forecast period.

Growth Drivers:

Increasing Cases of Infertility in Men and Women Drive Infertility Testing Market Growth

Infertility in males is a globally prevalent issue, with percentages varying from one region to another. According to the WHO, for ~20% of infertile couples, the problem is with male partners, whereas in 30% of couples, the infertility issue is with both partners. Common factors responsible for causing infertility in men are low levels of hormones made in the pituitary gland, deficiency in semen and semen quality, sexual issues affecting the entry of semen into the vaginal track, and presence of sperm antibodies. The most common cause responsible for low sperm count is varicocele, an enlarged vein in the testicle. According to the US Department of Health and Human Services, varicocele is present in about 40% of men suffering from infertility problems. The low sperm count leads to infertility in men, which boosts the infertility testing market.

The fertility rate is steadily declining across the world, owing to several factors such as late marriages and increasing age-related infertility. According to the WHO, there were an estimated 128.5 million new chlamydia infections in adults (15–49 years) worldwide in 2020. The prevalence of chlamydia infections in people aged 15–49 years was estimated at 4.0% for women and 2.5% for men. According to the Centers for Disease Control and Prevention (CDC), in the US, about 10% of women (6.1 million) aged 15 to 44 have trouble in getting or staying pregnant. Thus, the declining fertility rate propels the demand for infertility testing to determine the reasons for infertility in males and females, thereby driving the infertility testing market growth.

Customize Research To Suit Your Requirement

We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.

Get 10% FREE CUSTOMIZATION

Infertility Testing Market: Strategic Insights

Market Size Value in	US$ 424.20 million in 2022
Market Size Value by	US$ 820.08 million by 2030
Growth rate	CAGR of 8.6% from 2022 to 2030
Forecast Period	2022-2030
Base Year	2022

Akshay

Have a question?

Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

 Speak to Analyst

Report Segmentation and Scope:

The “infertility testing market analysis” has been carried out by considering the following segments: type, test kits, sample, and end user.

Segmental Analysis:

The infertility testing market, by type, is bifurcated into male infertility testing and female infertility testing. The female infertility testing segment held a larger market share in 2022. The male infertility testing segment is anticipated to register a higher CAGR of 9.2% during the forecast period. Increasing stress levels, obesity, smoking, and alcohol consumption are among the factors that contribute to male infertility. Furthermore, growing awareness regarding infertility, increasing research and development expenditure, initiatives by major infertility testing market players to launch their products, and changing lifestyles fuel the market growth for the male infertility testing segment.

By test kits, the infertility testing market is segmented into human follicular stimulating hormone (FSH) test kits, human chorionic gonadotropin (HCG) hormone test kits, luteinizing hormone (LH) test kits, and others. The human follicular stimulating hormone (FSH) test kits segment held the largest market share in 2022 and is anticipated to record the highest CAGR of 9.2% during the forecast period. The follicular stimulating hormone (FSH) test kit helps in measuring the concentration of FSH hormone present in the blood. The test is often used to assess FSH levels in men and women for various reasons such as fertility problems, menopause, or problems with sexual development. FSH helps control menstrual cycle of a woman and the growth of follicles that contain eggs in the ovaries. In men, FSH regulates the production and transport of sperm. The test is used to determine the sperm count. Therefore, an FSH test kit is an important diagnostic tool for assessing reproductive problems and other conditions related to hormonal imbalances. In addition, advanced biosimilar FSH products, regulatory approvals, market access, technological advances in FSH kit production, and a growing need for effective contraceptive options are predicted to accelerate the global market growth.

By sample, the infertility testing market is segmented into blood, urine, and others. The blood segment held the largest market share in 2022. The same segment is anticipated to register the highest CAGR of 9.1% during the forecast period. Infertility tests are usually blood tests to measure important hormones. Depending on the couple's situation, woman or man may require different blood tests. Blood tests that may be needed include follicular stimulating hormone (FSH), anti-Müllerian hormone (AMH), luteinizing hormone (LH), and others. In January 2021, health start-up Yesmom launched Asia's first at-home female fertility blood test kits to help women prioritize their reproductive health from the comfort of their homes.

By end user, the infertility testing market is categorized into hospitals & clinics, fertility centers, and homecare. The homecare segment held the largest market share in 2022 and is anticipated to register the highest CAGR of 9.0% during the forecast period. The segment is expected to grow owing to patient preference for self-monitoring of health conditions, easy access to fertility testing kits on e-commerce websites, availability of user-friendly and easy-to-use devices, and growing preference for the confidentiality of test results.

Adoption of Assisted Reproductive Technologies (ART) and In Vitro Fertilization (IVF) to Accelerate Infertility Testing Market

Growing awareness about infertility is expected to spur the demand for the treatments of IVF and ART in the coming years. Introduction of advanced treatment of intra cytoplasmic sperm injection and rising awareness about the medicinal and surgical procedures for IVF treatment are expected to drive the infertility testing market during the forecast period. According to UCSF Health, ~ 10% of infertility issues are due to unknown causes, and the other 30% are due to problems in male and female partners.

Common procedures performed in men include intracytoplasmic sperm injection (ICSI), epididymal aspirations, vassal aspiration, testicular sperm extraction, and mapping of the failing tests. Around 75% of men with a male factor have identifiable or treatable conditions affecting their fertility. Moreover, almost all men having male factor infertility are usually treatable with ARTs. Thus, the growing adoption of ART and IVF is likely to bring new infertility testing market trends in the coming years.

Regional Analysis:

The scope of the infertility testing market report entails North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.

In 2022, North America held the largest infertility testing market share. The market growth in this region is driven by the high occurrence of infertility, increasing awareness of infertility testing among men and women, rising age of first pregnancy among women, and easy availability of infertility test kits through e-commerce websites. Furthermore, the increasing prevalence of smoking and tobacco consumption will lead to an increase in infertility cases, propelling the market growth. Increasing testing awareness and the growing female population affected by PCOS are also accelerating the market growth.

The infertility testing market in Europe is expected to hold the third-largest share of the global market. The European market growth is driven by increasing awareness regarding infertility issues, diabetic population, and presence of a large number of players in the region along with government initiatives related to fertility. According to the European Society of Human, Reproductive and Embryology, infertility was estimated to affect over 25 million people across Europe in 2021. In Europe, one child per primary school class is born using assisted reproductive technologies (ART), and in the Nordic countries, between 2 and 7% of births come from ART. Spain is one of the preferred destination countries for infertility treatment as it has a progressive legal framework compared to other EU countries, high level of infertility professionals, excellent facilities, and advanced medical technologies. Fertility Europe (FE) is the umbrella organization of European associations involved with infertility issues in over 20 European countries. They aim to improve the rights of those affected by infertility, build a strong cross-border network amongst European patients to achieve and share best practices, promote social awareness about infertility and promote education in the area of the protection of reproductive health.

The infertility testing market in Asia Pacific is expected to witness the fastest growth rate of 9.1% during the forecast period. The regional market growth is attributed to an increase in the number of women affected by lifestyle disorders, rise in funding/investments in the development of infertility testing products, and upsurge in focus by international and domestic players on the Asia Pacific infertility test market.

Infertility Testing Market Report Scope

Industry Developments and Future Opportunities:

The infertility testing market forecast can help stakeholders in this marketplace plan their growth strategies. As per the press releases by leading players operating in the market, a few strategic developments are listed below:

• In July 2023, 2San, a respected global leader in self-diagnostic testing, partnered with Proov to launch its exclusive, easy-to-use at-home fertility tests at hand-selected Hy-Vee stores in eight Midwestern states.
• In January 2022, Kindbody, a leading fertility and family-building care provider, introduced Kind at Home, its consumer products division dedicated to support people throughout their reproductive journey. The initiative began with the introduction of user-friendly home fertility hormone tests for women and men.
• In December 2021, Carrot Fertility announced the launch of a new kit to help people monitor fertility hormones and related biomarkers at home. A customized, testing kit provides a more comprehensive picture of fertility health, enabling earlier action and interventions from the comfort of home.

Competitive Landscape and Key Companies:

Merck KgaA; Procter & Gamble; bioMerieux SA; Alere Inc.; Babystart Ltd.; bioZhena Corporation; Quidel Corporation; CENTOGENE N.V.; SCSA Diagnostics, Inc.; and Boditech Med Inc. are among the prominent companies profiled in the infertility testing market report. These companies focus on developing new technologies, upgrading existing products, and expanding their geographic presence to fulfil the growing consumer demand across the world.